Description
Memorial Sloan Kettering Cancer Center 3rd International Symposium on Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy 2023
- Include: 28 videos + 36 pdfs, size: 16.2 GB
- Target Audience: hematologist, immunologist, internist, oncologist, critical care physician
- Sample video: contact me for sample video
Information:
Friday, April 28, 2023, 9:00 AM – Saturday, April 29, 2023, 1:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY
Memorial Sloan Kettering Cancer Center This 3rd international Symposium will bring together a diverse group of experts and thought leaders in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss current advances in the field, mechanisms of toxicities, symptom burden, and late effects after HCT and cellular therapies along with best practices to prevent and treat these complications.
Memorial Sloan Kettering Cancer Center This unique 2-day program will be comprised of sessions dedicated to a wide range of pre-clinical, translational, and clinical topics, including cellular therapies as a model of accelerated aging, CAR T cell-related toxicities, infectious complications, decision science, the role of the gut microbiome in toxicities, debates on how to diagnose and treat difficult complications such as transplant-associated thrombotic microangiopathy, and several keynote lectures from world experts.
>> Who Should Attend
The target audience for this Symposium includes physicians, advanced practice providers (physician assistants and nurse practitioners), and nurses who treat or refer patients for hematopoietic cell transplantation or immune effector cell therapies (i.e., CAR T cells; tumor infiltrating lymphocytes, or T cell receptor therapy).
Available to in-person attendees only, the focus of this optional luncheon session is on Improving Outcomes with Active Acute Leukemia Undergoing Transplant — Do We Need to Reinduce Patients With Active AML?
Due to space, the luncheon is only available to 50 attendees and selection must be made during course registration. We do recommend early registration in order to secure your spot. Luncheon confirmation will be sent prior to the start of the Symposium.
We are pleased to invite the submission of abstracts for this Symposium. Abstracts will be selected on the basis of their scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and/or clinical research in progress will be accepted.
- Identify the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.
- Discuss the best practices in the prevention and treatment of toxicities and symptom burden after HCT and cellular therapy.
- Collaborate with a multidisciplinary group of colleagues to discuss, brainstorm, and plan future quality improvement and research efforts to reduce toxicities, improve the patient experience, and decrease non-relapse mortality.
Topics:
- A New, but Familiar Foe- IEC-HS (HLH).mp4
- A New, but Familiar Foe- IEC-HS (HLH).pdf
- Abstracts Biopsy proven kidney specific-thrombotic microangiopathy without systemic markers of hemolysis in patients with chronic kidney disease.pdf
- Abstracts CAR T-Associated Infection- A Single-Center, Five-Year Retrospective.pdf
- Abstracts Connected Care Remote Monitoring after Discharge from Inpatient Autologous or Allogeneic Stem Cell Transplant.pdf
- Abstracts Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD.pdf
- Abstracts Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy- a pharmacovigilance analysis of the FDA reporting system.pdf
- Abstracts Encouraging Outcomes after Second Hematopoietic Cell Transplants with Unrelated Cord Blood Grafts for Post-Transplant Relapse in Pediatric Patients.pdf
- Abstracts Free interleukin-18 is elevated in CD22 CAR T-cell associated hemophagocytic lymphohistiocytosis-like toxicities.pdf
- Abstracts Intrathecal Hydrocortisone for Treatment of Children and Young Adults with CAR T-cell Immune-Effector Cell Associated Neurotoxicity Syndrome.pdf
- Abstracts Successful incorporation of electronic patient reported outcomes using PROMIS-29 into standard of care after hematopoietic stem cell transplant.pdf
- Adoption or De-adoption of Evidence Into Practice in Transplantation and Cellular Therapy.mp4
- Adoption or De-adoption of Evidence Into Practice in Transplantation and Cellular Therapy.pdf
- Biomarkers of Aging in BMT and Next Steps in Our Field.mp4
- Biomarkers of Aging in BMT and Next Steps in Our Field.pdf
- Blocking IFN- Enhancement of CAR T cell Proliferation Without Increasing CRS.pdf
- CAR T Toxicities Panel Discussion Q&A.mp4
- CAR-HEMATOTOX- Prolonged Cytopenias After CAR T cell Therapy.mp4
- CAR-HEMATOTOX- Prolonged Cytopenias After CAR T cell Therapy.pdf
- Cellular Therapies as a Model of Accelerated Aging Panel Discussion Q&A.mp4
- CMV in the Lung- Pathogen, Paradigm, Puzzle.mp4
- CMV in the Lung- Pathogen, Paradigm, Puzzle.pdf
- Cognitive Impacts of Accelerated Aging in BMT.mp4
- Cognitive Impacts of Accelerated Aging in BMT.pdf
- Decision Science and Toxicities Panel Discussion Q&A.mp4
- FMT as Prophylactic Supportive Care.mp4
- FMT as Prophylactic Supportive Care.pdf
- FMT for Treatment of Acute GVHD.mp4
- FMT for Treatment of Acute GVHD.pdf
- Harmonization of Toxicity Definitions – Challenges – Process and Example.mp4
- Harmonization of Toxicity Definitions – Challenges – Process and Example.pdf
- HHV-6 Reactivation and Related Complications After HCT and CAR-T cell Therapies.pdf
- Immune Aging and Senolytics.mp4
- Immune Aging and Senolytics.pdf
- Incorporating Patient Reported Outcomes Into Standard of Care Practice.mp4
- Incorporating Patient Reported Outcomes Into Standard of Care Practice.pdf
- Infections as Toxicities Panel Discussions Q&A.mp4
- Integrating Patient Values and Preferences Into Treatment Decision Making.mp4
- Integrating Patient Values and Preferences Into Treatment Decision Making.pdf
- MSKTox2023_Brochure.pdf
- Nutrition and Microbiota in Allo-HCT.mp4
- Nutrition and Microbiota in Allo-HCT.pdf
- Nutrition – Microbiome and Toxicities Panel Discussion Q&A.mp4
- Nutritional Interventional Trial to Improve the Mircrobiome and Prevent Acute GVHD.mp4
- Nutritional Interventional Trial to Improve the Mircrobiome and Prevent Acute GVHD.pdf
- Parkinsonian Neurotoxicity After BCMA CAR T cells.mp4
- Parkinsonian Neurotoxicity After BCMA CAR T cells.pdf
- Plant Sequencing and Gut Microbiome in Allo-HCT.pdf
- Post CAR T Cell Infections.mp4
- Post CAR T Cell Infections.pdf
- Pulmonary Toxicities of Cellular Therapies.mp4
- Pulmonary Toxicities of Cellular Therapies.pdf
- Remote Performance Status Monitoring Using Wearables and PROs.mp4
- Remote Performance Status Monitoring Using Wearables and PROs.pdf
- Respiratory Viral Infections- Acute and Persistent Lung Effects.mp4
- Respiratory Viral Infections- Acute and Persistent Lung Effects.pdf
- Special Luncheon Debate.mp4
- Special Luncheon Debate.pdf
- Transplant as a Model of Accelerated Aging.mp4
- Transplant as a Model of Accelerated Aging.pdf
- Updates on the Diagnosis and Treatment of TA-TMA- Discussion with Experts.mp4
- Updates on the Diagnosis and Treatment of TA-TMA- Discussion with Experts.pdf
- Viral Specific T Cell Therapy for Polyomavirus- Overcoming BK and JC Virus After Cell Therapy.mp4
- Viral Specific T Cell Therapy for Polyomavirus- Overcoming BK and JC Virus After Cell Therapy.pdf
